ClinicalTrials.gg
RecruitingNCT03213002CAPTEMUpdated Nov 16, 2026

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

A Phase 1/2 interventional study of Capecitabine and Temozolomide in Glioblastoma Multiforme (GBM), Glioblastoma and Glioma of Brain, sponsored by Northwell Health. Recruiting at 1 site in United States. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Northwell Health · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2018; still recruiting 8 years 7 months later.
Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 232 studies testing temozolomide in Glioblastoma — 25 open to participants now, 35 under way, 2 of them phase 3. Temozolomide · Glioblastoma.

Planned enrollment
63rd of 221
67 · median 41
Started
2018
with 9 others
Phase 1/2
40 of 232
7 open now
Primary completion
2028-06
later than 25 of 34 live
Registered
167th of 232
by date

Among the 232 studies testing temozolomide in Glioblastoma, this one is the 63rd largest by planned enrollment of the 221 interventional ones that give a count, is one of 10 that started in 2018, is one of 40 in phase 1/2, reaches primary completion later than 25 of the 34 other live ones, and was the 167th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 232 studies testing temozolomide in Glioblastoma are open now, in 12 countries. Recruiting first, the newest first:

19 more — sign in →

By country, each count listing its studies:

All 25 open studies →

About temozolomide

Temozolomide: first FDA approval 1999 (TEMODAR), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies testing temozolomide in Glioblastoma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of administering the medication capecitabine along with temozolomide when you start your monthly regimen of oral temozolomide for the treatment of your newly diagnosed glioblastoma multiforme (GBM).

Capecitabine is an oral chemotherapy that is given to patients with other types of cancer. The study will evaluate whether the dosage of 1500 mg/m2 of capecitabine is tolerable after radiation, when taken along with temozolomide. It will also try to determine if the medication capecitabine helps patients respond to treatment for a longer period of time compared to just temozolomide alone, which is the standard of care.

Read the detailed description

There were an estimated 22,000 new cases of brain cancers in 2015 in the United States, and 15,000 deaths (Howlader et al., 2014). Glioblastoma (WHO IV), and Anaplastic Astrocytoma (WHO III), are the most common brain cancers, respectively, representing over 70% of all malignant gliomas (ABTA, 2015).

Though rare, there is no cure, and the prognosis for these tumors is poor. Survival at 5 years for all CNS cancers is approximately 33.3 % (Howlader et al., 2014). For GBM, the most lethal of the tumors, with the current standard of care median survival is 14.6 months (Walid, 2008). Relative survival with GBM at five years is approximately only 5% (Ostrom et al. CBTRUS 2014).

For newly diagnosed tumors, the current standard of care recommends a multi-modal approach with surgery to remove the tumor, when possible, followed by 6 weeks of radiation and a concurrent daily dose of temozolomide (Stupp et al. 2005). This is known as the Stupp protocol (Stupp et al. 2005). Patients then have a one-month rest period with no treatment, followed by "maintenance" temozolomide, given five days out of every 28 days, for a minimum of six months. Some providers keep patients on temozolomide beyond 6 months, or until disease progression.

Therefore, more therapies are needed to help improve survival, reduce time to recurrence and improve quality of life for these patients. This trial proposes to improve the current standard of care by enhancing the efficacy of an active drug temozolomide, currently used for treatment of GBM.

03

Conditions studied

  • Glioblastoma Multiforme (GBM)
  • Glioblastoma
  • Glioma of Brain
  • Glioblastoma, Adult
  • Brain Tumor
  • Brain Tumor, Primary
  • Brain Tumor Adult
  • Cancer
  • Brain Cancer
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be capable of giving .
  2. Have a pathology proven diagnosis of any of newly diagnosed Glioblastoma Multiforme WHO IV
  3. Have completed the first part of standard of care chemo-radiation (Stupp), for 6 weeks, and not started the maintenance phase of temozolomide
  4. Agree to use effective barrier while on treatment and for 2 months thereafter, if of
  5. Have a > 3 months
  6. Be between the ages of 18 to 74
  7. Have a performance status 70 or greater
  8. Be able to swallow pills and capsules
  9. Be able to tolerate oral chemotherapeutic medications, with no health threatening allergies or side effects, based on lab and clinical findings
  10. Have adequate bone marrow function, liver function and renal function before commencing therapy

Exclusion criteria

Exclusion Criteria:

  1. Prior chemotherapy with capecitabine or temozolomide for other prior . Patients previously treated with continuous infusion 5-FU or any schedule of DTIC, which are similar to capecitabine and temozolomide, respectively, will be excluded.
  2. Prior chemotherapies for newly diagnosed GBM or AA, other than temozolomide during radiation.
  3. Patients with a history of severe reaction to capecitabine, 5-FU, temozolomide (i.e. anaphylaxis or anaphylactic reactions),
  4. Serious medical or psychiatric illness preventing or treatment (e.g., serious infection)
  5. Prior malignancies in the last 5 years other than curatively treated carcinoma in-situ previously treated with curative intent (cancer free for the past one year).
  6. Performance status, \< 70
  7. Inability to swallow pills and capsules
  8. Concurrent chemotherapy or treatment for the active disease, including devices such as Optune, high dose vitamin supplements, or any other chemotherapy
  9. Patients taking concomitant medications such as Coumadin and phenytoin medications, need to be excluded because of interactions with capecitabine
  10. Patients with previously documented CAD will need to be evaluated by cardiology prior to start to help risk stratify for capecitabine tolerance
  11. Patients with renal insufficiency or hepatic insufficiency
  12. Patients with coagulopathies
  13. Women who are pregnant or lactating.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    Capecitabine amd Temozolomide

    Oral Capecitabine at 1500 mg/m2 divided into twice daily dosing, taken on days 1-14, and Temozolomide at 150 mg/m2 - 200 mg/m2 divided into twice daily dosing, taken on days 10-14; days 15-28 off.

    Drug: Capecitabine · Drug: Temozolomide

Interventions

  • Capecitabine at 1500 mg/m2

    Also known as: Xeloda

  • Temozolomide at 150 mg/m2 - 200 mg/m2

    Also known as: Temodar

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS)

    PFS will be estimated by calculating the proportion of patients who are alive at 6 months from treatment commencement and are progression-free.

    Time frame: 6 months

  2. Overall Survival (OS)

    OS will be calculated as the time from treatment initiation to the date of death.

    Time frame: 4 years

Secondary outcomes

  1. Composite overall response rate (CORR) through the Response Evaluation Criteria In Solid Tumors (RECIST)

    Subjects will be classified according to the RECIST criteria, which is a composite of MRI changes, clinical response and changes in steroid use.

    Time frame: 6 months

  2. Toxicities will be tabulated and graded according to the NCI Common Toxicity Criteria (CTCAE) version 4.03.

    Proportions of subjects experiencing these toxicities will be estimated using standard methods for proportions.

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Lenox Hill Brain Tumor Center
    New York, New York 10075, United States
    Recruiting
    • Tamika Wong, MPH · Contacttwong4@northwell.edu · 212-434-4836
    • John Boockvar, MD · Principal investigator
    • David Langer, MD · Sub investigator
    • Anuj Goenka, MD · Sub investigator
    • Christopher Filippi, MD · Sub investigator
    • Lalitha Anand, MD · Sub investigator
    • Sherese Fralin, NP · Sub investigator
    • Ashley Ray, NP · Sub investigator
    • Tamika Wong, MPH · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2018 (actual). Primary completion is estimated for Jun 2028, 123 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 123 months is above that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

Start moved once since we started tracking on Sep 25, 2026: Jun 2017 → Mar 2018, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2017
First posted
Jul 11, 2017
StartActual
Mar 25, 2018was Jun 2017
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 13, 2017→Mar 25, 2018
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Jun 13, 2017→Mar 25, 2018
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT03213002
Lead sponsor
Northwell Health
Responsible party
John Boockvar, MD Zucker SOM @Hofstra/Northwell (Prinicpal INvesigator, Northwell Health) — Principal investigator
First posted
Jul 11, 2017
Start date
Mar 25, 2018
Primary completion
Jun 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

John Boockvar, MD
Contact
jboockvar@northwell.edu
212-434-3900
Tamika Wong, MPH
Contact
twong4@northwell.edu
212-434-4836
John Boockvar, MD
principal investigator · Lenox Hill Hospital-Northwell Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Temozolomide

Start the discussion